Stockscreener 앱 받기
45.77
1.51%
0.755
전일 마감가:
$45.02
열려 있는:
$44.64
하루 거래량:
67,673
Relative Volume:
0.09
시가총액:
$2.60B
수익:
$1.28B
순이익/손실:
$-222.15M
주가수익비율:
-11.19
EPS:
-4.09
순현금흐름:
$145.52M
1주 성능:
-0.72%
1개월 성능:
+5.67%
6개월 성능:
-1.32%
1년 성능:
-16.11%
1일 변동 폭
$44.64
$45.76
1주일 범위
$44.28
$46.92
52주 변동 폭
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
명칭
Livanova Plc
전화
4402033250662
주소
20 EASTBOURNE TERRACE, LONDON
LIVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
45.76 | 2.60B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
136.55 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.99 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
398.00 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.34 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.75 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | 개시 | Goldman | Buy |
| 2024-09-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | 재확인 | Needham | Buy |
| 2024-02-20 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Hold |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2023-04-14 | 개시 | Mizuho | Neutral |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-02-24 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-03 | 개시 | Goldman | Buy |
| 2021-08-20 | 재확인 | Needham | Buy |
| 2021-07-20 | 업그레이드 | Needham | Hold → Buy |
| 2021-03-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-01-05 | 다운그레이드 | Needham | Buy → Hold |
| 2020-09-02 | 개시 | Robert W. Baird | Outperform |
| 2020-06-26 | 재확인 | Needham | Buy |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-02-28 | 재확인 | Needham | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-06-08 | 개시 | Stifel | Buy |
| 2018-05-31 | 재확인 | Needham | Buy |
| 2018-02-28 | 재확인 | Needham | Buy |
모두보기
Livanova Plc 주식(LIVN)의 최신 뉴스
Global Neurostimulation Devices Market to grow at a CAGR - openPR.com
(LIVN) Investment Report - news.stocktradersdaily.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com Nigeria
Wearable Cardioverter Defibrillators (WCD) Market Growth | - openPR.com
LivaNova Shareholders Approve New Incentive Plans - Investing.com
LivaNova Shareholders Approve New Incentive Plans By Investing.com - Investing.com Canada
LivaNova Shareholders Approve Key Incentive Plans at AGM - TipRanks
Livanova petitions CMS to drop CED mandate for VNS for depression - BioWorld MedTech
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com South Africa
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com South Africa
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com India
LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com
Artificial Heart Lung Machines Market Projected to Witness - openPR.com
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Th - GuruFocus
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus
LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider
VNS therapy shows sustained seizure reduction in study - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - Business Wire
LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider
LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa
LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice
Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus
LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy - GuruFocus
LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression | LIVN Stock News - GuruFocus
LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - StreetInsider
LivaNova Announces 12-month Data from OSPREY Study - Medical Product Outsourcing
Vagus Nerve Stimulation (VNS) Market Poised for Breakthrough Growth: From $488.5M in 2022 to $836.1M by 2032 - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Electroceuticals Market Generated Opportunities, Future - openPR.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com Australia
LivaNova's SWOT analysis: medical device firm's stock faces growth hurdles - Investing.com
(LIVN) Technical Data - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG - Defense World
LivaNova faces $360M liability after court ruling By Investing.com - Investing.com South Africa
LivaNova (NASDAQ:LIVN) Raised to Outperform at Wolfe Research - Defense World
LivaNova faces $360M liability after court ruling - Investing.com Australia
Livanova Plc (LIVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Livanova Plc 주식 (LIVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bianchi Francesco | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
10,938 |
| SCHERMERHORN TODD C | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
9,473 |
| KOZY WILLIAM A | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
4,840 |
0 |
33,148 |
| Barry James Christopher | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
4,772 |
| Story Brooke | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
6,892 |
| Enxing Seng Stacy | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
12,161 |
| WILVER PETER M | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
7,148 |
| Tezel Ahmet | Chief Innovation Officer |
Jun 15 '25 |
Option Exercise |
0.00 |
2,967 |
0 |
2,967 |
| Bolton Stephanie | President, Global Epilepsy |
Mar 30 '25 |
Option Exercise |
0.00 |
6,024 |
0 |
15,586 |
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
1.35%
0.75%
자본화:
|
볼륨(24시간):